



## Current Funding Opportunities — August 2017

### **1) Limited Competition: Lasker Clinical Research Scholars Transition Award (R00) ([PAR-17-450](#))**

**SPONSORS:** National Institutes of Health, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of Nursing Research

***Synopsis:*** The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility.

Application Receipt/Submission Date(s): Multiple dates

### **2) Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment (U01) ([RFA-CA-17-029](#))**

**SPONSOR:** National Cancer Institute

***Synopsis:*** The purpose of this initiative is to establish an Academic-Industrial Partnership Program to develop new and/or validate existing technologies, methods and assays for the capture and quantification of tumor associated cells, DNA, RNA or exosomes in body fluids of patients with early stage disease or those at high risk; as well as distinguishing cancer from benign disease; or aggressive from indolent cancers. The precompetitive alliances with industry will harmonize and validate technologies, methods and assays associated with liquid biopsies.

Application Receipt Date(s): October 24, 2017 and January 23, 2018

**3) Collaborative Research Network for Fusion Oncoproteins in Childhood Cancers (U54)**  
**[\(RFA-CA-17-049\)](#)**

**SPONSOR: National Cancer Institute**

***Synopsis:*** This Funding Opportunity Announcement is associated with the *Beau Biden Cancer MoonshotSM Initiative* that is intended to accelerate cancer research. The purpose of this FOA is to promote research on fusion oncoproteins in childhood cancers. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation E. Intensify research on the major drivers of childhood cancers: Improve our understanding of fusion oncoproteins in pediatric cancer and use new preclinical models to develop inhibitors that target them.

Application Receipt Date: November 15, 2017